Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2929 Arch Street, Suite 600 PHILADELPHIA PA 19104 |
Tel: | N/A |
Website: | https://www.cabalettabio.com |
IR: | See website |
Key People | ||
Steven Nichtberger Chairman of the Board, President, Chief Executive Officer, Co-Founder | Anup Marda Chief Financial Officer | Gwendolyn Knowlton Binder-Scholl President - Science and Technology |
Michael Gerard General Counsel, Secretary | David J. Chang Chief Medical Officer | Arun Das Chief Business Officer |
Business Overview |
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cabaletta Bio Inc revenues was not reported. Net loss increased 28% to $67.7M. Higher net loss reflects Research and development increase of 39% to $49.9M (expense), Stock-based Compensation in SGA increase of 64% to $5.8M (expense), Stock-based Compensation in R&D increase of 65% to $5.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.81 to -$1.65. |
Employees: | 101 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $401.33M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$73.23M as of Dec 31, 2023 |
Net annual income (TTM): | -$67.68M as of Dec 31, 2023 |
Free cash flow (TTM): | -$54.24M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 48,241,615 as of Mar 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |